- Home
- AGAE vs PASG Comparison
AGAE vs PASG Comparison
Compare AGAE & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$0.36
HOLD
Current Price
$12.90
Company Overview
Basic Information| Metric | AGAE | PASG |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 28.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | AGAE | PASG |
|---|---|---|
| Price | $0.36 | $12.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $34.50 |
| AVG Volume (30 Days) | ★ 662.7K | 85.7K |
| Earning Date | 11-19-2025 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,938,232.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.33 | $5.12 |
| 52 Week High | $3.79 | $20.00 |
Technical Indicators
Market Signals| Indicator | AGAE | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 42.98 | 48.79 |
| Support Level | $0.33 | $13.33 |
| Resistance Level | $0.39 | $16.12 |
| Average True Range (ATR) | 0.04 | 2.26 |
| MACD | -0.00 | -0.28 |
| Stochastic Oscillator | 19.71 | 31.51 |
Price Performance
Historical Comparison AGAE
PASG
About AGAE Allied Gaming & Entertainment Inc.
Allied Gaming & Entertainment Inc is an experiential entertainment company focused on providing a growing world of gamers with various experiences through renowned assets, products, and services.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.